The use of faecal microbiota transplant as treatment for recurrent or refractory<i>Clostridium difficile</i>infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Mullish, Benjamin H.; Quraishi, Mohammed Nabil; Segal, Jonathan; McCune, Victoria L.; Baxter, M.; Marsden, Gemma; Moore, David; Colville, A.; Bhala, Neeraj; Iqbal, Tariq; Settle, Chris; Kontkowski, Graziella; Hart, Ailsa; Hawkey, Peter M.; Goldenberg, Simon; Williams, Horace R T

doi:10.1136/gutjnl-2018-316818

Cited by 278 publications

(229 citation statements)

References 129 publications

Supporting

Mentioning

205

Contrasting

Unclassified

Order By: Relevance

“…The main challenges with FMT are as follows (Figure ): Integrative therapy: This is needed to establish stool‐banking and rigorous quality assurance measures in clinical practice Standardization of process flow . (a) Preparation of fecal material: the amount of stool, whether fresh or frozen, the choice of solvents, and whether the environment is aerobic or anaerobic.…”

Section: Therapeutic Strategy Of Fmt In Uc and Controversymentioning

confidence: 99%

Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment

Guo

Liu

Hao

2020

J of Digest Diseases

190

110

View full text Add to dashboard Cite

Gut microbiota constitute the largest reservoir of the human microbiome and are an abundant and stable ecosystem—based on its diversity, complexity, redundancy, and host interactions This ecosystem is indispensable for human development and health. The integrity of the intestinal mucosal barrier depends on its interactions with gut microbiota. The commensal bacterial community is implicated in the pathogenesis of inflammatory bowel disease (IBD), including ulcerative colitis (UC). The dysbiosis of microbes is characterized by reduced biodiversity, abnormal composition of gut microbiota, altered spatial distribution, as well as interactions among microbiota, between different strains of microbiota, and with the host. The defects in microecology, with the related metabolic pathways and molecular mechanisms, play a critical role in the innate immunity of the intestinal mucosa in UC. Fecal microbiota transplantation (FMT) has been used to treat many diseases related to gut microbiota, with the most promising outcome reported in antibiotic‐associated diarrhea, followed by IBD. This review evaluated the results of various reports of FMT in UC. The efficacy of FMT remains highly controversial, and needs to be regularized by integrated management, standardization of procedures, and individualization of treatment.

show abstract

Section: Therapeutic Strategy Of Fmt In Uc and Controversymentioning

confidence: 99%

Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment

Guo

Liu

Hao

2020

J of Digest Diseases

190

110

View full text Add to dashboard Cite

show abstract

“…Fecal donors are either close relatives, family members or unrelated individuals. However, where possible, fecal material is best sourced from a healthy unrelated individual, from a centralized stool bank . To eliminate the risk of inadvertently transmitting infection, donors in preparation of FMT should be screened according to an established protocol .…”

Section: Introductionmentioning

confidence: 99%

Fecal microbiota transplantation in cancer management: Current status and perspectives

Chen

Jin

et al. 2018

Intl Journal of Cancer

236

161

View full text Add to dashboard Cite

The human gut is home to a large and diverse microbial community, comprising about 1,000 bacterial species. The gut microbiota exists in a symbiotic relationship with its host, playing a decisive role in the host's nutrition, immunity and metabolism. Accumulating studies have revealed the associations between gut dysbiosis or some special bacteria and various cancers. Emerging data suggest that gut microbiota can modulate the effectiveness of cancer therapies, especially immunotherapy. Manipulating the microbial populations with therapeutic intent has become a hot topic of cancer research, and the most dramatic manipulation of gut microbiota refers to fecal microbiota transplantation (FMT) from healthy individuals to patients. FMT has demonstrated remarkable clinical efficacy against Clostridium difficile infection (CDI) and it is highly recommended for the treatment of recurrent or refractory CDI. Lately, interest is growing in the therapeutic potential of FMT for other diseases, including cancers. We briefly reviewed the current researches about gut microbiota and its link to cancer, and then summarized the recent preclinical and clinical evidence to indicate the potential of FMT in cancer management as well as cancer‐treatment associated complications. We also presented the rationale of FMT for cancer management such as reconstruction of intestinal microbiota, amelioration of bile acid metabolism, and modulation of immunotherapy efficacy. This article would help to better understand this new therapeutic approach for cancer patients by targeting gut microbiota.

show abstract

“…In addition, placement of a nasointestinal tube is associated with aspiration pneumonia, which can be avoided by colonic infusion . Bowel preparation was included in most protocols for FMT, and it was recommended in the guidelines for the treatment of CDI via FMT issued by the British Society of Gastroenterology and Healthcare Infection Society . Bowel preparation plays an important role in modulating the success rate of FMT by colonoscopy, as inadequate bowel preparation severely compromises efficacy .…”

Section: Gut Microbiota‐based Diagnosis and Therapiesmentioning

confidence: 99%

Gut microbiome interventions in human health and diseases

Nie

Wang

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

Ongoing studies have determined that the gut microbiota is a major factor influencing both health and disease. Host genetic factors and environmental factors contribute to differences in gut microbiota composition and function. Intestinal dysbiosis is a cause or a contributory cause for diseases in multiple body systems, ranging from the digestive system to the immune, cardiovascular, respiratory, and even nervous system. Investigation of pathogenesis has identified specific species or strains, bacterial genes, and metabolites that play roles in certain diseases and represent potential drug targets. As research progresses, gut microbiome–based diagnosis and therapy are proposed and applied, which might lead to considerable progress in precision medicine. We further discuss the limitations of current studies and potential solutions.

show abstract

The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Cited by 278 publications

References 129 publications

Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment

Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment

Fecal microbiota transplantation in cancer management: Current status and perspectives

Gut microbiome interventions in human health and diseases

Contact Info

Product

Resources

About